NASDAQ: PRTAProthena Corp Public Ltd Co Stock
$20.76+0.35 (+1.71%)
Updated Sep 10, 2024
PRTA Price
$20.76
Fair Value Price
N/A
Market Cap
$1.12B
52 Week Low
$18.69
52 Week High
$56.04
P/E
-21.85x
P/B
1.92x
P/S
5.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$217.25M
Earnings
-$50.92M
Gross Margin
100%
Operating Margin
-28.26%
Profit Margin
-23.4%
Debt to Equity
0.11
Operating Cash Flow
-$99M
Beta
1.26
Next Earnings
Nov 4, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PRTA Overview
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PRTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRTA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRTA is good value based on its book value relative to its share price (1.92x), compared to the US Biotechnology industry average (6.29x)
P/B vs Industry Valuation
PRTA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRTA due diligence checks available for Premium users.
Be the first to know about important PRTA news, forecast changes, insider trades & much more!
PRTA News
Valuation
PRTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-21.85x
Industry
-138.13x
Market
23.55x
PRTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.92x
Industry
6.29x
PRTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRTA's financial health
Profit margin
Revenue
$132.0M
Net Income
$66.9M
Profit Margin
50.7%
PRTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PRTA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$645.6M
Liabilities
$63.6M
Debt to equity
0.11
PRTA's short-term assets ($585.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRTA's short-term assets ($585.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRTA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PRTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$16.0M
Investing
-$143.0k
Financing
$444.0k
PRTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRTA vs Biotech Stocks
Prothena Public Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.